Pediatric mucormycosis associated with COVID-19: A systematic review of clinical cases

Enferm Infecc Microbiol Clin (Engl Ed). 2024 Jan 11:S2529-993X(24)00005-4. doi: 10.1016/j.eimce.2023.11.006. Online ahead of print.

Abstract

The occurrence of mucormycosis has been observed in individuals with COVID-19. However, there is limited information on the epidemiological factors, presentation, diagnostic certainty, and outcome of this infection in children. PubMed, MEDLINE, Scopus, Embase, Web of Science, LitCovid, and back-references of the identified manuscripts were systematically searched from December 2019 to March 2023. We have identified 14 cases of pediatric mucormycosis in patients with COVID-19. The median age of patients was 10.7 years. Among these cases, 10 were associated with active COVID-19. In 7 cases, the patients had pre-existing diabetes mellitus and concomitant diabetic ketoacidosis. Corticosteroids were administered to treat COVID-19 in 7 of the patients. The most common clinical presentation of the disease was rhino-orbital cerebral mucormycosis. Seven patients died (50%). Given the high mortality rate, clinicians should maintain a high level of clinical suspicion of mucormycosis in pediatric patients with COVID-19.

Keywords: Children; Diabetes mellitus; Mucorales; Niños; Pandemia; Pandemic; SARS-CoV-2.

Publication types

  • Review